Explore the words cloud of the NEURONET project. It provides you a very rough idea of what is the project "NEURONET" about.
The following table provides information about the project.
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL
|Coordinator Country||Spain [ES]|
|Total cost||2˙353˙125 €|
|EC max contribution||1˙199˙125 € (51%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-03-01 to 2022-02-28|
Take a look of project's partnership.
|1||SYNAPSE RESEARCH MANAGEMENT PARTNERS SL||ES (MADRID)||coordinator||588˙250.00|
|2||ALZHEIMER EUROPE||LU (LUXEMBOURG)||participant||307˙625.00|
|3||NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE||UK (MANCHESTER)||participant||303˙250.00|
|4||Eli Lilly and Company Limited||UK (Basingstoke)||participant||0.00|
|5||F. HOFFMANN-LA ROCHE AG||CH (BASEL)||participant||0.00|
|6||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
|7||PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG||UK (LONDON)||participant||0.00|
|8||SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT||FR (Chilly Mazarin)||participant||0.00|
|9||TAKEDA DEVELOPMENT CENTRE EUROPE LTD||UK (LONDON)||participant||0.00|
The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide. This will be achieved through the following specific objectives: 1) creation of an overall platform for efficient collaboration, communication and operational synergies among present and future IMI ND projects; 2) designing systems to map and analyse information regarding actions, initiatives and partnerships, assessing impact of the individual projects, remaining gaps and global value of the programme for stakeholders; 3) supporting the management of the programme (timelines, dependencies, synergies and key results across projects); 4) proactively detecting needs, opportunities and transferable best practices of projects and to connect them; 5) providing support to the projects by organising tools, services, expert advice and guidelines/recommendations on common issues; 6) promoting enhancement and coordination of communication across the IMI neurodegeneration projects, increasing programme visibility, outreaching to key stakeholders and establishing relationships with initiatives in the field; and 7) preparing and securing the long-term sustainability of NEURONET itself. Achievement of these objectives will necessarily rely on buy-in from existing and future projects in the IMI ND portfolio, and effective connections with other programmes and initiatives in Europe and beyond, including stakeholder representation. For this, the Consortium has been constituted by very active partners in a variety of IMI ND projects and related initiatives with specialists in areas like complex/project management, data sharing & re-use, drug development, patient engagement, communication, sustainability and regulatory/HTA interactions.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEURONET" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEURONET" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.Read More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More